Prosecution Insights
Last updated: April 19, 2026
Application No. 17/281,239

Monovalent Selective Cation Exchange Membrane

Final Rejection §103
Filed
Sep 27, 2021
Examiner
ROLLAND, ALEX A
Art Unit
1759
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Evoqua Water Technologies LLC
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
3y 7m
To Grant
74%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
271 granted / 585 resolved
-18.7% vs TC avg
Strong +27% interview lift
Without
With
+27.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
53 currently pending
Career history
638
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
61.4%
+21.4% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 585 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 9-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 4/25/25. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over WO 2011025867 to Lin in view of US 5389449 to Afeyan. Claims 1-4, 6-8: Lin teaches a method for manufacturing an ion exchange membrane that forms a cross-linked ion-transferring polymeric layer on a surface of a polymeric microporous substrate. The process includes the polymeric microporous substrate (pg. 9) coated with a solution of charged monomer (i.e., iongenic monomer), multifunctional monomer, and polymerization initiator and polymerized/crosslinked by heat or UV (pg. 13). Lin does not teach adsorbing a further chlorosulfonated methacrylate group to this cross-lined ion-transferring polymeric layer or the subsequent aminating and functionalization. However, Afeyan teaches the surface modification of ion exchange membranes (abstract). The process applies a halosulfonating agent onto the substrate (4:61-65), such as a chlorosulfonating agent (4:66-68), aminating the chlorosulfonated surface by applying PEI (5:50-63), and functionalizing the amine groups in the PEI (i.e., quaternized; positively charged) (6:10-13). Afeyan does not teach the chlorosulfonating agent includes a methacrylate group, although is open to any agent that can react with various substrate to produce chlorosulfone groups on the substrate surface (5:42-48). Turning back to Lin, the main monomer used by Lin is 2-SEM. By comparison, the claimed chlorosulfonated methacrylate compound is 2-methacryloyloxy ethylsulfonyl. PNG media_image1.png 314 548 media_image1.png Greyscale PNG media_image2.png 334 406 media_image2.png Greyscale These compositions are the same except for the substitution of and -OH group for a -Cl group. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to practice the method of Lin followed by the method of Afeyan to produce a functionalized ion exchange membrane. It further would have been obvious to use the chlorinated 2-SEM as the chlorosulfonating agent in order to maintain compositional consistency across the membrane structure, better incorporate it into the cross-linked ion-transferring polymeric layer, and avoids the problem of forming undesirable sulfonic acid groups (5:11-32). Claim 5: Afeyan teaches PEI with a MW from 600-1000000 Da (5:59). Response to Arguments Applicant's arguments filed 8/19/25 have been fully considered but they are not persuasive. As Applicant points out, Afeyan teaches both an amine that is quaternized or derivatized. In both of these cases, an R group is added to the amine. Adding an R group to the amine is functionalizing it. This is also functionalizing with a charged compound layer in an analogous manner as aminating to form an amine group layer. That is, it is internally consistent with the way that “layer” is being used in the claim. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEX A ROLLAND whose telephone number is (571)270-5355. The examiner can normally be reached M-F 10-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Curtis Mayes can be reached at 5712721234. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALEX A ROLLAND/Primary Examiner, Art Unit 1759
Read full office action

Prosecution Timeline

Sep 27, 2021
Application Filed
Sep 21, 2021
Response after Non-Final Action
May 14, 2025
Non-Final Rejection — §103
Aug 19, 2025
Response Filed
Oct 20, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594529
PREPARATION METHOD OF TI3C2TX MXENE QUANTUM DOT (MQD)-MODIFIED POLYAMIDE (PA) REVERSE-OSMOSIS (RO) MEMBRANE
2y 5m to grant Granted Apr 07, 2026
Patent 12595622
Fabric Substrate and Manufacturing Method Thereof
2y 5m to grant Granted Apr 07, 2026
Patent 12589390
DETECTION CHIP AND MODIFICATION METHOD THEREFOR
2y 5m to grant Granted Mar 31, 2026
Patent 12586764
PLASMA SHOWERHEAD TREATMENT METHODS
2y 5m to grant Granted Mar 24, 2026
Patent 12577667
CYCLIC ALKYL AMINO CARBENE (CAAC) DEPOSITION BY TRANSMETALLATION
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
74%
With Interview (+27.4%)
3y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 585 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month